Paclitaxel versus sirolimus eluting stents in diabetic patients: does stent type and/or stent diameter matter? Long-term clinical outcome of 2429-patient multicenter registry
Catheterization and Cardiovascular Interventions, 05/09/2012
Clinical Article
Tarantini G et al. – In this large observational study, paclitaxel–eluting stents (PES) and sirolimus–eluting stents (SES) were equally safe and efficacious in diabetic patients undergoing PCI in clinical practice, regardless of the stent size.
Methods- Data were obtained from an observational, multicenter registry of 2,429 consecutive patients with DM who underwent PCI between August 2003 and August 2009 with SES (n=1370) or PES (n=1059).
- Data were analyzed separately for patients with small stents (<3.0 mm, n= 1274) vs only large (≥3.0 mm, n=1155).
- At Cox adjusted analysis of the overall cohort, there was no significant difference between SES and PES with regard to death/myocardial infarction (D/MI) (p=0.6) or target lesion revascularization (TLR) (p=0.3) either in ‘small–stent’ (D/MI, p=0.8; TLR, p=0.2) or large stent group (D/MI, p=0.8; TLR, p=0.4) throughout 1 to 5–year follow–up.
- These results were confirmed by sensitivity, propensity–score matched analysis (717 matched pairs) that failed to find differences in the safety and efficacy between SES and PES.
